TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7/8/24 08:00 | 7/3/24 | FULC | Fulcrum Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sapir Alex | MA | DO | See Rema | M.d | 491 | 3.27 | 0 | 150 | 346 | 193 | D | ||||||||||||||
3/5/24 16:15 | 3/4/24 | FULC | Fulcrum Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sapir Alex | MA | DO | See Rema | P | 492 | 11.35 | 0 | 43 | New | 43 | D | ||||||||||||||
5/19/23 16:17 | 5/19/23 | PHAS | Phasebio Pharmaceuticals Inc | DE | Health | Drug | Pharmaceutical Preparations | Sapir Alex | DE | D | M.d | 0 | 0.00 | 0 | 4 | New | 4 | D | |||||||||||||||
8/15/18 16:27 | 8/14/18 | DOVA | Dova Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sapir Alex | NC | DO | P,CEO | P | 495 | 22.83 | 0 | 22 | 46 | 69 | I | ||||||||||||||
12/27/17 16:32 | 12/22/17 | DOVA | Dova Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sapir Alex | NC | DO | P,CEO | M.d | 100 | 3.73 | 0 | 27 | 133 | 47 | D | ||||||||||||||
7/7/17 06:44 | 7/5/17 | DOVA | Dova Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Sapir Alex | NC | DO | P,CEO | P | 342 | 17.00 | 0 | 20 | New | 20 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |